Tenecteplase Drug Market Research Report – Forecast to 2027

Global Tenecteplase Drug Market Research Report, by Application (Myocardial Infarction, Stroke, DVT), Dosage(Intravenous Dosage, Intracatheter Instillation ), End-User (Hospitals & Clinics, Surgical Centers, Research Centers) – Global Forecast Till 2027

ID: MRFR/Pharma/4940-HCR | | Region: Global | 100 pages

Market Scenario


Tenecteplase drug is an enzyme derived through recombinant DNA technology from a human cell line. This enzyme is used to treat thrombus (blood clots) it is also called as clot-busting drug. Tenecteplase is a bioengineered variant of the activase drug. The key factor responsible for influencing this market is the increasing cases of deep vein thrombosis, stroke, increase in blood pressure patient. According to the  American Heart Association 2017, report every year almost 790,000 Americans have a heart attack. Coronary artery diseases are increasing day by day due to change in lifestyle. These factors enhance the tenecteplase drug market. However, factors such as the high cost of surgical procedures, allergic reaction, side effects associated with the drug are expected to restrict the market growth during the forecast period.


Segmentation


The global tenecteplase drug market is segmented on the basis of application, dosage and end users.


The Tenecteplase drug market, by application segmented into myocardial infarction, stroke, DVT. The Tenecteplase drug market, by dosage intravenous dosage and intracatheter instillation dosage. Intravenous dosage is sub-segmented into an adult and geriatric and intracatheter instillation dosage is sub-segmented into adult, children, and adolescents weighing 30 kg, infants. On the basis of end-user, it is segmented into hospitals and clinics, surgical centers, research centers. On the basis of region, the global tenecteplase drug market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is sub-segmented into North America and South America. The North American region is further segmented into the US and Canada. The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the UK, Spain, and the rest of Western Europe. The Asia-Pacific region is sub-segmented into Japan, China, India, Australia, the Republic of Korea, and the rest of Asia-Pacific. The Middle Eastern and African region is sub-segmented into the United Arab Emirates, Saudi Arabia, Oman, Kuwait, Qatar, and the rest of the Middle East and Africa.


Key players


Some of the key players in the global tenecteplase drug market are Boehringer Ingelheim International GmbH, Genentec Inc., Gennova pharmaceutical, Rewine pharmaceuticals, Hisun USA, Emcure Pharmaceutical, Merck Ltd. and Crunchbase Inc., and others.


Regional Market Summary


Global Tenecteplase Drug Market Share (%), by Region, 2017


Tenecteplase Drug Market Share


Sources: National Cancer Institute, Cancer Research UK, the American Cancer Society, Inc, US Department of Health and Human Services National Institutes of Health


It is estimated that North America dominated the global tenecteplase drug market owing to the increasing innovations in clinical practice, myocardial infection, and access to stroke treatment in this region. According to an article published by CDC in October 2015, report 350,000 to 900,000 cases of Venous thromboembolism (VTE) are estimated every year in the US. This influences the market growth in this region.


Europe stood second largest in the tenecteplase drug market due to increase in the incidents of stroke. According to UK stroke, Organization stroke is the 10th leading cause of death in the world, 34,883 mortality cases of stroke found in the UK in 2015. Due to an increase in hypertension and high blood pressure, the cases of stroke are increasing which can be a major reason for increasing the tenecteplase drug market in this region.


Asia-Pacific was projected to be the fastest growing region for the global tenecteplase drug market in 2017. The market is expected to witness growth owing to the rising prevalence of hypertension, changing lifestyle, and increasing cardiac disease in the population. According, to the Australian Bureau of Statistics 2015, 4.1 million Australians had high blood pressure. Such a high incidence of high blood pressure favors the market growth in this region.


The Middle East and Africa holds the least share of the global tenecteplase drug market due to the presence of poor health expenditure and economically diverse countries. However, the market is expected to witness growth due to increasing cancer care programs in the Middle East.


Market Segmentation and Key Market Players


Global Tenecteplase Drug Market, by Application



  • Myocardial Infarction

  • Stroke

  • Deep Vein Thrombosis


Global Tenecteplase Drug Market, by Dosage



  • Intravenous dosage

  • Adult

  • Geriatric

  • Intracatheter instillation dosage

  • Adult

  • Children and Adolescents Weighing 30 Kg

  • Infants


Global Tenecteplase Drug Market, by End-User



  • Hospitals and clinics

  • Surgical center

  • Research centers

  • Others


Global Tenecteplase Drug Market, by Region



  • Americas

  • Europe

  • Asia-Pacific

  • Middle East & Africa


Intended Audience



  • Pharmaceutical companies

  • Biotechnological institutes

  • Government and private laboratories

  • Research and Development (R&D) companies

  • Medical research laboratories

  • Market research and consulting service providers



Report Scope:
Report Attribute/Metric Details
  Market Size   Significant Value
  CAGR   4. 2019-2027: Substantial CAGR
  Base Year   2019
  Forecast Period   2027
  Historical Data   2018
  Forecast Units   Value (USD Billion)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Application, Dosage And End Users
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Boehringer Ingelheim International GmbH, Genentec Inc., Gennova pharmaceutical, Rewine pharmaceuticals, Hisun USA, Emcure Pharmaceutical, Merck Ltd. and Crunchbase Inc
  Key Market Opportunities

  • North America dominated the global tenecteplase drug market owing to the increasing innovations in clinical practice, myocardial infection, and access to stroke treatment in this region
  • Europe stood second largest in the tenecteplase drug market due to increase in the incidents of stroke
  •   Key Market Drivers

  • Increasing cases of deep vein thrombosis, stroke
  • Increase in blood pressure patient


  • Frequently Asked Questions (FAQ) :


    Tenecteplase drug market growth would be affected due to high surgical costs, allergic reactions, and side-effects.

    The applications included in tenecteplase drug market report are myocardial infarction, stroke, and DVT.

    Dosage mentioned in teneteplase drug market is intravenous dosage and intracatheter instillation dosage.

    The included end users are hospitals & clinics, surgical centers, and research centers.

    The players involved in the tenecteplase drug market are Gennova Pharmaceutical, Boehringer Ingelheim International GmbH, Emcure Pharmaceutical, Merck Ltd. Genentec Inc., Hisun USA, Rewine Pharmaceuticals, and Crunchbase Inc., and others.

    TABLE OF CONTENT

    Chapter 1. Report Prologue

    Chapter 2. Market Introduction

    2.1 Definition

    2.2 Scope of the Study

    2.2.1 Research Objective

    2.2.2 Assumptions

    2.2.3 Limitations

    Chapter 3. Research Methodology

    3.1 Introduction

    3.2 Primary Research

    3.3 Secondary Research

    3.4 Market Size Estimation

    Chapter 4. Market Dynamics

    4.1 Drivers

    4.2 Restraints

    4.3 Opportunities

    4.4 Challenges

    4.5 Macroeconomic Indicators

    4.6 Technology Trends & Assessment

    Chapter 5. Market Factor Analysis

    5.1 Porter’s Five Forces Analysis

    5.1.1 Bargaining Power of Suppliers

    5.1.2 Bargaining Power of Buyers

    5.1.3 Threat of New Entrants

    5.1.4 Threat of Substitutes

    5.1.5 Intensity of Rivalry

    5.2 Value Chain Analysis

    5.3 Investment Feasibility Analysis

    5.4 Pricing Analysis

    Chapter 6. Global Tenecteplase Drug Market, by Application

    6.1 Introduction

    6.2 Myocardial Infarction

    6.3 Stroke

    6.4 Deep Vein Thrombosis

    Chapter 7. Global Tenecteplase Drug Market, by Dosage

    7.1 Introduction

    7.2 Intravenous dosage

    7.2.1 Adult

    7.2.2 Geriatric

    7.3 Intracatheter instillation dosage

    7.3.1 Adult

    7.3.2 Children and Adolescents weighting 30kg

    7.3.3 Infants


    Chapter 8. Global Tenecteplase Drug Market, by End-User

    8.1 Introduction

    8.2 Hospitals and clinics

    8.3 Surgical centers

    8.4 Research centers

    8.5 Other

    Chapter 9. Global Tenecteplase Drug Market, by Region

    9.1 Introduction

    9.2 America

    9.2.1 North America

    9.2.1.1 US

    9.2.1.2 Canada

    9.2.2 South America

    9.3 Europe

    9.3.1 Western Europe

    9.3.1.1 Germany

    9.3.1.2 France

    9.3.1.3 Italy

    9.3.1.4 Spain

    9.3.1.5 UK

    9.3.1.6 Rest of Western Europe

    9.3.2 Eastern Europe

    9.4 Asia-Pacific

    9.4.1 Japan

    9.4.2 China

    9.4.3 India

    9.4.4 Australia

    9.4.5 Republic of Korea

    9.4.6 Rest of Asia-Pacific

    9.5 Middle East & Africa

    9.5.1 United Arab Emirates

    9.5.2 Saudi Arabia

    9.5.3 Oman

    9.5.4 Kuwait

    9.5.5 Qatar

    9.5.6 Rest of the Middle East & Africa

    Chapter 10. Company Landscape

    10.1 Introduction

    10.2 Market Share Analysis

    10.3 Key Development & Strategies

    10.3.1 Key Developments

    Chapter 11 Company Profiles

    11.1 Boehringer Ingelheim International GmbH

    11.1.1 Company Overview

    11.1.2 Type Overview

    11.1.3 Financials

    11.2.4 Key Developments

    11.1.5 SWOT Analysis

    11.2 Genentec Inc.,

    11.2.1 Company Overview

    11.2.2 Type Overview

    11.2.3 Financial Overview

    11.2.4 Key Developments

    11.2.5 SWOT Analysis

    11.3 Gennova pharmaceutical

    11.3.1 Company Overview

    11.3.2 Type Overview

    11.3.3 Financial Overview

    11.3.4 Key Development

    11.3.5 SWOT Analysis

    11.4 Rewine pharmaceuticals

    11.4.1 Company Overview

    11.4.2 Type/Business Segment Overview

    11.4.3 Financial Overview

    11.4.4 Key Development

    11.4.5 SWOT Analysis

    11.5 Hisun USA

    11.5.1 Company Overview

    11.5.2 Type Overview

    11.5.3 Financial overview

    11.5.4 Key Developments

    11.5.5 SWOT Analysis

    11.6 Emcure Pharmaceutical

    11.6.1 Company Overview

    11.6.2 Type Overview

    11.6.3 Financial Overview

    11.6.4 Key Developments

    11.6.5 SWOT Analysis

    11.7 Merck ltd.

    11.7.1 Overview

    11.7.2 Type Overview

    11.7.3 Financials

    11.7.4 Key Developments

    11.7.5 SWOT Analysis

    11.8 CrunchBase INC.

    11.8.1 Overview

    11.8.2 Type Overview

    11.8.3 Financials

    11.8.4 Key Developments

    11.8.5 SWOT Analysis

    11.12 Others

    Chapter 12 Appendix

    LIST OF TABLES

    Table 1 Global Tenecteplase Drug Market Industry Synopsis, 2020–2027

    Table 2 Global Tenecteplase Drug Market Estimates & Forecast, 2020–2027, (USD Million)

    Table 3 Global Tenecteplase Drug Market, by Region, 2020–2027, (USD Million)

    Table 4 Global Tenecteplase Drug Market, by Application, 2020–2027, (USD Million)

    Table 5 Global Tenecteplase Drug Market, by Dosage, 2020–2027, (USD Million)

    Table 6 Global Tenecteplase Drug Market, by End-User, 2020–2027, (USD Million)

    Table 7 North America: Tenecteplase Drug Market, by Application, 2020–2027, (USD Million)

    Table 8 North America: Tenecteplase Drug Market, by Dosage, 2020–2027, (USD Million)

    Table 9 North America: Tenecteplase Drug Market, by End-User, 2020–2027, (USD Million)

    Table 10 US: Tenecteplase Drug Market, by Application, 2020–2027, (USD Million)

    Table 11 US: Tenecteplase Drug Market, by Dosage, 2020–2027, (USD Million)

    Table 12 US: Tenecteplase Drug Market, by End-User, 2020–2027, (USD Million)

    Table 13 Canada: Tenecteplase Drug Market, by Application, 2020–2027, (USD Million)

    Table 14 Canada: Tenecteplase Drug Market, by Dosage, 2020–2027, (USD Million)

    Table 15 Canada: Tenecteplase Drug Market, by End-User, 2020–2027, (USD Million)

    Table 16 South America: Tenecteplase Drug Market, by Application, 2020–2027, (USD Million)

    Table 17 South America: Tenecteplase Drug Market, by Dosage, 2020–2027, (USD Million)

    Table 18 South America: Tenecteplase Drug Market, by End-User, 2020–2027, (USD Million)

    Table 19 Europe: Tenecteplase Drug Market, Application, 2020–2027, (USD Million)

    Table 20 Europe: Tenecteplase Drug Market, by Dosage, 2020–2027, (USD Million)

    Table 21 Europe: Tenecteplase Drug Market, by End-User, 2020–2027, (USD Million)

    Table 22 Western Europe: Tenecteplase Drug Market, by Application, 2020–2027, (USD Million)

    Table 23 Western Europe: Tenecteplase Drug Market, by Dosage, 2020–2027, (USD Million)

    Table 24 Western Europe: Tenecteplase Drug Market, by End-User, 2020–2027, (USD Million)

    Table 25 Eastern Europe: Tenecteplase Drug Market, by Application, 2020–2027, (USD Million)

    Table 26 Eastern Europe: Tenecteplase Drug Market, by Dosage, 2020–2027, (USD Million)

    Table 27 Eastern Europe: Tenecteplase Drug Market, by End-User, 2020–2027, (USD Million)

    Table 28 Asia-Pacific: Tenecteplase Drug Market, by Application, 2020–2027, (USD Million)

    Table 29 Asia-Pacific: Tenecteplase Drug Market, by Dosage, 2020–2027, (USD Million)

    Table 30 Asia-Pacific: Tenecteplase Drug Market, by End-User, 2020–2027, (USD Million)

    Table 31 Middle East & Africa: Tenecteplase Drug Market, by Application, 2020–2027, (USD Million)

    Table 32 Middle East & Africa: Tenecteplase Drug Market, by Dosage, 2020–2027, (USD Million)

    Table 33 Middle East & Africa: Tenecteplase Drug Market, by End-User, 2020–2027, (USD Million)

    LIST OF FIGURES

    Figure 1 Research Process

    Figure 2 Segmentation for the Global Tenecteplase Drug Market

    Figure 3 Market Dynamics for the Global Tenecteplase Drug Market

    Figure 4 Global Tenecteplase Drug Market Share, by Application 2020

    Figure 6 Global Tenecteplase Drug Market Share, by Dosage, 2020

    Figure 6 Global Tenecteplase Drug Market Share, by End-User, 2020

    Figure 7 Global Tenecteplase Drug Market Share, by Region, 2020

    Figure 8 North America Tenecteplase Drug Market Share, by Country, 2020

    Figure 9 Europe Prescribed Health Apps Share, by Country, 2020

    Figure 10 Asia-Pacific Tenecteplase Drug Market Share, by Country, 2020

    Figure 11 Middle East & Africa Tenecteplase Drug Market Share, by Country, 2020

    Figure 12 Global Tenecteplase Drug Market: Company Share Analysis, 2020 (%)

    Figure 13 Boehringer Ingelheim International GmbH: Key Financials

    Figure 14 Boehringer Ingelheim International GmbH: Segmental Revenue

    Figure 15 Boehringer Ingelheim International GmbH: Geographical Revenue

    Figure 16 Genentec Inc., Key Financials

    Figure 17 Genentec Inc., Segmental Revenue

    Figure 18 Genentec Inc., Geographical Revenue

    Figure 19 Gennova pharmaceutical: Key Financials

    Figure 20 Gennova pharmaceutical: Segmental Revenue

    Figure 21 Gennova pharmaceutical: Geographical Revenue

    Figure 22 Rewine pharmaceuticals: Key Financials

    Figure 23 Rewine pharmaceuticals: Segmental Revenue

    Figure 24 Rewine pharmaceuticals: Geographical Revenue

    Figure 25 Emcure Pharmaceutical: Key Financials

    Figure 26 Emcure Pharmaceutical: Segmental Revenue

    Figure 27 Emcure Pharmaceutical: Geographical Revenue

    Figure 28 Merck ltd.: Key Financials

    Figure 29 Merck ltd.: Segmental Revenue

    Figure 30 Merck ltd.: Geographical Revenue

    Figure 31 Crunchbase Inc.: Key Financials

    Figure 32 Crunchbase Inc.: Segmental Revenue

    Figure 33 Crunchbase Inc.: Geographical Revenue